尿液药物检测样本中芬太尼、海洛因、甲基苯丙胺和可卡因的分析物浓度
这项横断面研究分析了2013年1月1日至2023年8月22日美国49州和哥伦比亚特区物质使用障碍治疗诊所的921931份尿液药物检测样本,用液相色谱-串联质谱检测芬太尼、海洛因(6-单乙酰吗啡)、可卡因(苯甲酰爱康宁)和甲基苯丙胺浓度,经肌酐归一化后取对数分析。结果显示2023年芬太尼、甲基苯丙胺和可卡因调整浓度均高于2013年,海洛因浓度则下降,且药物浓度在美国人口普查区之间存在差异。作者认为这些物质的暴露及非法药物供应已发生根本变化,需加强监测并加快对芬太尼和/或兴奋剂暴露者的治疗。
要点
- 2023年尿液芬太尼调整浓度为38.23(95%CI 35.93-40.67)ng/mg肌酐,2013年为4.61(95%CI 3.59-5.91)ng/mg肌酐,十年间上升。
- 2023年甲基苯丙胺调整浓度为3461.59(95%CI 3271.88-3662.30)ng/mg肌酐,2013年为665.27(95%CI 608.51-727.32)ng/mg肌酐。
- 2023年可卡因调整浓度为1122.23(95%CI 1032.41-1219.87)ng/mg肌酐,2013年为559.71(95%CI 524.69-597.06)ng/mg肌酐。
- 2023年海洛因调整浓度为58.36(95%CI 48.26-70.58)ng/mg肌酐,低于2013年的146.59(95%CI 136.06-157.92)ng/mg肌酐。
- 药物浓度在美国各人口普查区之间存在差异。
适用人群与场景
- 2013年1月1日至2023年8月22日期间,美国49个州和哥伦比亚特区物质使用障碍治疗诊所中年龄18岁及以上、由临床医生根据医疗需要开具尿液药物检测的患者。
研究设计与关键结果
- 研究类型为横断面研究,共纳入921931份唯一尿液药物检测样本,来自549042名男性(59.6%),中位年龄34岁(IQR 27-44岁)。
- 样本经液相色谱-串联质谱检测芬太尼、海洛因(6-单乙酰吗啡)、可卡因(苯甲酰爱康宁)和甲基苯丙胺,浓度经肌酐归一化后取对数,用Mann-Kendall趋势检验分析时间趋势。
- 2023年芬太尼调整浓度为38.23(95%CI 35.93-40.67)ng/mg肌酐,2013年为4.61(95%CI 3.59-5.91)ng/mg肌酐。
- 2023年甲基苯丙胺调整浓度为3461.59(95%CI 3271.88-3662.30)ng/mg肌酐,2013年为665.27(95%CI 608.51-727.32)ng/mg肌酐。
- 2023年可卡因调整浓度为1122.23(95%CI 1032.41-1219.87)ng/mg肌酐,2013年为559.71(95%CI 524.69-597.06)ng/mg肌酐。
- 2023年海洛因调整浓度为58.36(95%CI 48.26-70.58)ng/mg肌酐,2013年为146.59(95%CI 136.06-157.92)ng/mg肌酐,期间下降。
- 药物浓度在美国各人口普查区之间存在差异。
证据类型、等级与局限
- 证据类型:横断面研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,芬太尼、甲基苯丙胺和可卡因尿液浓度的上升以及海洛因浓度的下降提示美国许多地区这些物质的暴露及非法药物供应已发生根本变化。
- 作者认为,需要加强监测举措,并加快对芬太尼和/或兴奋剂暴露个体的治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The US is experiencing a protracted drug overdose crisis primarily associated with exposure to illicitly manufactured fentanyl (IMF), methamphetamine, and cocaine. Overdose risk and treatment responses may be directly affected by absolute drug exposure concentrations and drug use prevalence.
OBJECTIVE: To quantify changes in absolute drug exposure concentrations from 2013 to 2023.
DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study analyzed urine drug testing (UDT) results from urine specimens collected between January 1, 2013, and August 22, 2023, in 49 states and the District of Columbia. Urine specimens were obtained from patients aged 18 years or older who presented to substance use disorder treatment clinics. The UDT was ordered by clinicians based on medical necessity.
EXPOSURES: Urine specimens were analyzed for the following drugs or metabolites (analytes tested in parentheses): fentanyl (fentanyl), heroin (6-monoacetylmorphine), cocaine (benzoylecgonine), and methamphetamine (methamphetamine) using liquid chromatography with tandem mass spectrometry.
MAIN OUTCOMES AND MEASURES: Relative concentrations of fentanyl, heroin, cocaine, and methamphetamine. Creatinine-normalized drug concentration values were log-transformed prior to visualization and statistical analyses. The Mann-Kendall trend test was performed to examine trends over time. To estimate the geospatial and temporal patterns of drug concentration, a second series of models (1 for each drug) with an interaction effect for clinic location and collection year were fit.
RESULTS: A total of 921 931 unique UDT samples were collected from patients (549 042 males [59.6%]; median [IQR] age, 34 [27-44] years). The adjusted fentanyl concentration in urine specimens was 38.23 (95% CI, 35.93-40.67) ng/mg creatinine in 2023 and 4.61 (95% CI, 3.59-5.91) ng/mg creatinine in 2013. The adjusted methamphetamine concentration was 3461.59 (95% CI, 3271.88-3662.30) ng/mg creatinine in 2023 and 665.27 (95% CI, 608.51-727.32) ng/mg creatinine in 2013. The adjusted cocaine concentration was 1122.23 (95% CI, 1032.41-1219.87) ng/mg creatinine in 2023 and 559.71 (95% CI, 524.69-597.06) ng/mg creatinine in 2013. The adjusted heroin concentration was 58.36 (95% CI, 48.26-70.58) ng/mg creatinine in 2023 and 146.59 (95% CI, 136.06-157.92) ng/mg creatinine in 2013. Drug concentrations varied across US Census divisions.
CONCLUSIONS AND RELEVANCE: This cross-sectional study found that absolute concentrations of fentanyl, methamphetamine, and cocaine in urine specimens increased from 2013 to 2023, with a decrease in heroin concentration during that period. The findings suggest that exposure to these substances, as well as the illicit drug supply, has fundamentally changed in many parts of the US, highlighting the need to reinforce surveillance initiatives and accelerate efforts to treat individuals with IMF and/or stimulant exposure.
参考来源
- Huhn AS, Whitley P, Bolin BL, et al. Fentanyl, Heroin, Methamphetamine, and Cocaine Analyte Concentrations in Urine Drug Testing Specimens. JAMA Netw Open. 2024. PMID: 39446323. doi:10.1001/jamanetworkopen.2024.41063
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。